Browse Studies — Arctuva

Phase 2

A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture …

Spinal Cord InjurySpinal Cord InjuriesInjuries, Spinal Cord+11 more

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07742553

Phase 2

Locomotor Training With Testosterone to Promote Bone and Muscle Health

This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with loc…

Spinal Cord InjurySpinal Cord InjuriesTrauma, Nervous System+17 more

Estimated

~$10 – $6,250

North Florida Foundation for Research and EducationNCT04460872

Phase 4

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium label…

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more

Estimated

~$10 – $7,500

VA Greater Los Angeles Healthcare SystemNCT06706921

Phase 1

A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combi…

mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, MaleUrogenital Diseases, Male+3 more

Estimated

~$10 – $8,750

Celcuity IncNCT06190899